This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaudy, C.
Right arrow Articles by Goudeau, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaudy, C.
Right arrow Articles by Goudeau, A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2003, p. 3615-3622, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3615-3622.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Significance of Pretreatment Analysis of Hepatitis C Virus Genotype 1b Hypervariable Region 1 Sequences To Predict Antiviral Outcome

Catherine Gaudy,1 Alain Moreau,1 Pascal Veillon,2 Stephanie Temoin,1 Francoise Lunel,2 and Alain Goudeau1*

Département de Microbiologie Médicale et Moléculaire EA 3250, Université François Rabelais, F37044 Tours Cedex,1 Laboratoire de Virologie, CHU, F49033 Angers Cedex 01, France2

Received 11 November 2002/ Returned for modification 13 January 2003/ Accepted 17 May 2003

The heterogeneity of hypervariable region 1 (HVR1), located at the amino terminus of the E2 envelope, may be involved in resistance to alpha interferon (IFN-{alpha}) treatment. We investigated whether peculiar HVR1 domain profiles before treatment were associated with the maintenance of sensitivity or the appearance of resistance to treatment. Fifteen patients infected with hepatitis C virus genotype 1b and treated with IFN with or without ribavirin were selected. Ten responded to treatment (groups R1 and R2) and five did not (group NR). The amino acid sequences of 150 naturally occurring HVR1 variants present in the serum before therapy were compared in relation to treatment outcome. HVR1 variants from the NR group contained a constant nonantigenic amino acid segment that was not found in HVR1 variants from the R groups.

* Corresponding author. Mailing address: Département de Microbiologie Médicale et Moléculaire EA 3250, Faculté de Médecine, 2, bis Boulevard Tonnellé, F37044 Tours Cedex, France. Phone: (33) 2 47 47 69 97. Fax: (33) 2 47 47 36 10. E-mail: goudeau{at}med.univ-tours.fr.

Journal of Clinical Microbiology, August 2003, p. 3615-3622, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3615-3622.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Humphreys, I., Fleming, V., Fabris, P., Parker, J., Schulenberg, B., Brown, A., Demetriou, C., Gaudieri, S., Pfafferott, K., Lucas, M., Collier, J., Huang, K.-H. G., Pybus, O. G., Klenerman, P., Barnes, E. (2009). Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection. J. Virol. 83: 11456-11466 [Abstract] [Full Text]  
  • Qin, H., Shire, N. J., Keenan, E. D., Rouster, S. D., Eyster, M. E., Goedert, J. J., Koziel, M. J., Sherman, K. E., and the Multicenter Hemophilia Cohort Study Group, (2005). HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 105: 533-541 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»